Conference Description:

Gene therapy developers are striving to platform their process development to more quickly and cost-effectively bring their drugs to market, meaning optimizing upstream process development has never been a greater priority for this community.

The first Gene Therapy Process Development is your only specific gene therapy event with optimizing process development with the transgene at the forefront of mind.

Join your biopharma colleagues from the likes of Ultragenyx, Janssen, REGENXBIO and more, for two days of cutting-edge talks on cell-line development, scale-up, transfection, purification, analytics, and regulation. This must-attend meeting is your chance to share ideas, successes, and challenges, and capitalize on the latest advances in process development to bring safe and effective drugs to patients faster.

Tickets: https://go.evvnt.com/1943329-2?pid=154
Time: 8:00 AM - 4:00 PM

Prices:
Drug Developer Pricing - 2-Day Conference: USD 2999.00,
Solution Provider Pricing - 2-Day Conference: USD 3799.00

Speakers: Brad Mickey, Executive Director, Manufacturing and Operations Site Head, Astellas Gene Therapies, David McNally, Head of Viral Vector Technology, University of Massachusetts Chan Medical School, Gary Todd, VP - Head of Technologies, Lacerta Therapeutics, Huiren Zhao, Principal Scientist, Amgen Inc., Jun Li, Associate Director - Upstream Process Development and Gene Therapy, Ultragenyx, Margaret Liu, Professor at the William G. Lowrie Department of Chemical and Biomolecular Engineering, James Comprehensive Cancer Centre, Oluwatoyin Areo, Research Advisor, Bioassay Development, Ping Liu, Associate Director and Head of Cell Line Development, REGENXBIO, Po-Yi Ho, Senior Scientist, Analytical Development, Carbon Biosciences, Pranav Joshi, Associate Director - Upstream Process Development, Gene Therapy Program at The University of Pennsylvania, Scott Burger, Principal Consultant, Advanced Cell and Gene Therapy, Seema Bhatlekar, Gene Therapy and Process Development Scientist, Janssen, Steve Greenway, Associate Director - Upstream Process Development, Vesigen Therapeutics, Vincent Wiegmann, Upstream Process Development Senior Scientist I, MeiraGTx, Yi Pu, Group Head, Prime Medicine